Hepatitis B in Ireland, 2017. by unknown
    
Suggested citation: HSE Health Protection Surveillance Centre. Hepatitis B Annual Report 2017 
Dublin: HSE HPSC; 2018 
 
© HSE Health Protection Surveillance Centre, 2018. Reproduction is authorised, provided source is 
acknowledged 
 
 
 
 
1 
Key Facts 
Number of cases, 2017:          532 
Crude notification rate, 2017:  11.2/100,000 population 
The number of notifications of hepatitis B increased by 9% in 2017 compared to 2016 (n=487). 
The vast majority of hepatitis B cases notified in Ireland are chronically infected, most of whom 
have migrated to Ireland from hepatitis B endemic countries. There were 31 acute cases (recent 
infections) notified in 2017. Most acute cases of hepatitis B in Ireland are sexually acquired. 
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Background 
Hepatitis B is a vaccine preventable disease caused by the hepatitis B virus. It is 
transmitted through percutaneous or mucocutaneous contact with the blood or body fluids 
of an infected person. Symptoms of acute infection include anorexia, abdominal discomfort, 
nausea and vomiting, often followed by jaundice. Symptoms are frequently milder and  
jaundice is less likely in children. Acute infection is usually asymptomatic in infants. After 
acute infection, the risk of developing chronic hepatitis B declines with increasing age.1 
Approximately 90% of infants infected at birth will develop chronic infection, compared to 
20-50% of children infected between the ages of one and five years. Only 1-10% of those 
infected as older children or adults will develop chronic hepatitis B. An estimated 15-25% of 
those who develop chronic infection with die prematurely of cirrhosis of the liver or 
hepatocellular carcinoma. 
 
The prevalence of hepatitis B in the general population in Ireland is low (less than 1%). This 
is similar to other northern European countries (0.1-0.7%).2 Most cases occur in defined 
risk groups; such as people with multiple sexual partners, sexual or household contacts of 
known cases, people who inject drugs (PWID) and people who were born in countries with 
intermediate (2-7%) or high (>8%) hepatitis B endemicity. 
 
Methods 
The figures presented in this report are based on data extracted from the Computerised 
Infectious Disease Reporting (CIDR) System on 9th October 2018. These figures may differ 
from those published previously due to ongoing updating of the notification data on CIDR. 
Notification rates are expressed per 100,000 population and are calculated using the 2016 
census. 
 
Epidemiology  
Number of notifications and notification rates 
There were 532 notifications of hepatitis B in 2017 (11.2/100,000 population). This was an 
increase of 9% compared to 2016 (n=487, 10.2/100,000 population), but was similar to the 
numbers reported for 2015. Hepatitis B notifications more than halved between 2008 
(n=898, 21.2/100,000 population) and 2013 (n=423, 9.2/100,000 population), but recent 
trends indicate that the notification rate has stabilised and that this decline is not continuing 
(figure 1). 
Notification rates for each HSE area for the past four years are shown in figure 2. The 
highest notification rate in 2017 was in HSE E (20/100,000 population, n=343, 65% of 
notifications).  
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All cases were laboratory confirmed. Eighty seven percent (n=465) of the 532 notifications 
contained information on acute/chronic status. Of these, 93% (n=434, 9.1/100,000 
population) of cases were chronically infected (long-term infection) and 7% (n=31, 
0.7/100,000 population) were acutely infected (recent infection). Both acute and chronic 
cases of hepatitis B are notifiable in Ireland. 
 
Figure 1. Number of hepatitis B notifications in Ireland by acute/chronic status, 1997-2017 
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Figure 2. Hepatitis B notification rates/100,000 population by HSE area in Ireland, 2014-2017 
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Acute cases (recent infections) 
The number of acute cases of hepatitis B notified in Ireland has been low in recent years 
and continued in the same vein in 2017 with 31 cases notified compared to 32 cases in 
2016 (figure 3). Seventy one percent (n=22) of acute cases in 2017 were male. Cases 
ranged in age from 22 to 70 years. The overall median age at notification was 41 years. 
Male cases were older on average, with a median age of 47.5 years compared to 39 years 
for females. The median age of male acute cases of hepatitis B has increased in recent 
years (figure 3). The age and sex distribution of acute cases notified in 2017 is shown in 
figure 4.  
 
Information on risk factor was available for 74% (n=23) of the acute cases notified in 2017. 
Of these, 70% (n=16) were likely to have been sexually acquired. Eleven were heterosexual 
(six females and five males), four were men who have sex with men (MSM) and sexual 
orientation was not reported for one. One additional case was infected through injecting 
drug use, one had travelled to an endemic country and one case reported tattooing as the 
most likely risk factor for infection. No risk factor was identified for four cases despite public 
health follow up.  
 
Country of birth was specified for 90% (n=28) of acute cases. Almost three quarters (71%, 
n=20) were born in Ireland. Country of infection was reported for 77% (n=24), two thirds 
(n=16) of whom were infected in Ireland. The reason for testing was known for 90% (n=28) 
of cases and most were tested because they were symptomatic (n=24, 86%). 
 
Figure 3. Number of acute cases of hepatitis B notified in Ireland, by sex and median age, 2004-
2017 
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Figure 4. Age and sex-specific notification rates/100,000 population for acute cases of hepatitis B 
in Ireland, 2017 
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Chronic cases (long-term infections) 
Chronic hepatitis B notification rates halved between 2008 and 2013, but have since 
stabilised. Figure 5 shows the number of chronic cases notified annually between 2004 and 
2017. Of the 434 chronic cases notified in 2017, 58% (n=250) were male, 41% (n=178) 
were female and sex was not reported for 6 cases. Cases ranged in age from 1 to 79 years, 
with 90% (n=389) of chronic cases aged between 20 and 54 years when notified (figure 5). 
Male cases were slightly older than female cases with a median age at notification of 35 
years compared to 33 for females (overall median: 35 years). The age and sex distribution 
of chronic cases notified in 2017 is shown in figure 6.  
 
Although primary risk factor was reported for less than one fifth of chronic cases in 2017, 
data on country of birth or asylum seeker status was available for 71% (n=308). Of these, 
83% (n=255) were either born in a hepatitis B endemic country (hepatitis B surface antigen 
prevalence >2%) or were asylum seekers. Most of these cases are likely to have been 
infected outside Ireland, but the actual mode of acquisition of infection is often not known. 
Where country of birth was reported (67%, n=289), the most common birth countries were 
in central or eastern Europe (41%, n=117), Asia (24%, n=70), sub-Saharan Africa (23%, 
n=66) and western Europe (7%, n=19). Of those born in western Europe, 14 were born in 
Ireland.  
 
The reason for testing was known for 74% (n=319) of chronic cases. The main reasons 
were: routine health screening (21%, n=66), antenatal screening (19%, n=59), re-testing of 
known cases (not previously notified) (17%, n=55), asylum seeker screening (15%, n=47), 
STI screening (8%, n=25), experiencing symptoms (6%, n=18) and participation in the 
emergency department blood borne virus screening programme in St James’s Hospital 
(4%, n=13). 
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Figure 5. Number of chronic cases of hepatitis B notified in Ireland, by sex and median age, 2004-
2017 
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Figure 6. Age and sex-specific notification rates/100,000 population for chronic cases of hepatitis 
B in Ireland, 2017 
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Immigration and hepatitis B notifications 
Hepatitis B notifications are influenced by trends in immigration to Ireland. The large 
increase in the number of hepatitis B cases between 1997 and 2008 (figure 1) was mainly 
due to significant numbers of people migrating to Ireland from hepatitis B endemic 
countries. Figure 7 shows trends in hepatitis B (acute or chronic) notifications alongside 
immigration estimates from the Central Statistics Office.3 
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Figure 7: Number of hepatitis B notifications in Ireland and estimated number of immigrants from 
EU16-28* & non EU/EEA countries (excluding Canada, United States and Australia), 2004-2017 
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Co-infections 
Co-infection with other bloodborne viruses, such as hepatitis C and HIV, can lead to more 
severe liver disease and an increased risk of liver cancer in people with hepatitis B 
infection. Four hepatitis B cases notified in 2017 were co-infected with hepatitis C (0.8%) 
and eight additional cases were co-infected with HIV (1.5%). Other sexually transmitted 
infections were also reported for ten cases.  
 
 
Discussion 
Hepatitis B notifications increased by 9% in 2017 (n=532) compared to 2016, but remained 
at significantly lower levels compared to peak notification numbers in 2008 (n=899). The 
vast majority of hepatitis B notifications in Ireland are chronic cases, most of whom 
migrated to Ireland from hepatitis B endemic countries. The number of acute cases of 
hepatitis B notified in 2017 was similar to 2016 and remained relatively low. Most acute 
cases are sexually acquired in Ireland. There is a safe and effective vaccine for hepatitis B. 
Immunisation is recommended for those who change sex partner frequently, MSM, 
attendees at STI clinics and others at increased risk of infection or more severe disease. 
Universal hepatitis B vaccination was introduced in Ireland in 2008 as part of the primary 
vaccine programme for infants 
(https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/chapter9.pdf).  
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Further information available on HPSC website 
http://www.hpsc.ie/a-z/hepatitis/hepatitisb/ 
http://www.hpsc.ie/a-z/hepatitis/hepatitisb/hepatitisbreports/ 
http://www.hpsc.ie/a-z/hepatitis/hepatitisb/slidesets/ 
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